| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.0076 | 0.9 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.9 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |